Research & Development: Page
-
Scott Olson/Staff via Getty Images
Prediction markets are putting a price on pharma’s secrets. Here’s what companies need to know.
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information.
By Sy Mukherjee • Sept. 8, 2026 -
Justin Sullivan via Getty Images
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
By PharmaVoice Staff • Sept. 4, 2026 -
Explore the Trendline➔
Getty Images
TrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
Joe Raedle via Getty Images
As measles outbreaks soar, where does drug R&D stand?
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up against a tense market environment.
By Alexandra Pecci • Sept. 4, 2026 -
Getty Images
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
By Jonathan Gardner • Sept. 3, 2026 -
Andrew Harnik via Getty Images
China’s clinical trial boom under scrutiny after 3 deaths come to light
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
By Kelly Bilodeau • Sept. 3, 2026 -
Getty Images
The hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.
By Sy Mukherjee • Sept. 1, 2026 -
Getty Images
Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.
By Alexandra Pecci • Aug. 31, 2026 -
Sponsored by ICON
Advances in risk assessment shift the calculus of early intervention trials for MASLD
How risk prediction is making early intervention trials in MASLD more feasible.
By Jolanta M. Wichary, MD, Vice President, Therapeutic Area Lead, Gastroenterology and Hepatology and Jack Martin, MD, FACC, Senior Director, Cardiovascular Therapeutics, Drug Development Solutions, ICON • Aug. 31, 2026 -
Alamy
New data could widen use of AstraZeneca, Amgen immune disease drug
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
By Delilah Alvarado • Aug. 28, 2026 -
Permission granted by Argenx
Q&A // First 90 DaysA single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
By Meagan Parrish • Aug. 28, 2026 -
Permission granted by GSK
Pharma’s new CEOs to watch
New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.
By Kelly Bilodeau • Aug. 27, 2026 -
Getty Images
3 takeover targets in immunology
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&AIs AI finally proving its worth in drug R&D?
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&ALegend’s interim CEO sees a shorter path to the next era of CAR-T
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
By Sy Mukherjee • Aug. 25, 2026 -
Claudio Ventrella via Getty Images
3 potential blockbusters beyond obesity to watch
Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial upside.
By Alexandra Pecci • Aug. 24, 2026 -
Permission granted by Tyra Biosciences
Tyra’s one-drug, three-indication bet nears its first phase 2 test
What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline.
By Alexandra Pecci • Aug. 21, 2026 -
Getty Images
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.
By PharmaVoice Staff • Aug. 21, 2026 -
Getty Images
OpinionThe scientific research pharma leaders keep sharing — and why
Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.
By Kelly Bilodeau • Aug. 20, 2026 -
Permission granted by Courtesy of Helus Pharma
Q&A // First 90 DaysHow Helus’ new CEO plans to scale its psychedelic drug pipeline
Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?
By Kelly Bilodeau • Aug. 18, 2026 -
Getty Images
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
By Alexandra Pecci • Aug. 17, 2026 -
Courtesy of BMS
BMS builds big in Texas; Regeneron backs would-be rival
BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.
By PharmaVoice Staff • Aug. 14, 2026 -
Sean Gallup / Staff via Getty Images via Getty Images
BioNTech’s oncology pivot comes with a new CEO
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.
By Kelly Bilodeau • Aug. 14, 2026 -
Getty Images
Biotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
By Alexandra Pecci • Aug. 13, 2026 -
Permission granted by Image courtesy of Formation Bio
Profile // First 90 DaysFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
By Alexandra Pecci • Aug. 12, 2026 -
Getty Images
Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?
While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.
By Kelly Bilodeau • Aug. 10, 2026
Previous
